SCHEMBL3556474

SCHEMBL3556474

c1coc(CN2CCC[N]CC2)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.37
HRH1 P35367 2/20 0.37
LTA4H P09960 1/20 0.35
SIGMAR1 Q99720 1/20 0.34
TLR8 Q9NR97 4/20 0.32
TLR7 Q9NYK1 4/20 0.32
TLR9 Q9NR96 3/20 0.32
WNT1 P04628 1/20 0.32
GSK3B P49841 1/20 0.32
DYRK1A Q13627 1/20 0.32
LRRK2 Q5S007 1/20 0.32
ADORA2A P29274 1/20 0.31
ADORA1 P30542 1/20 0.31
CCR5 P51681 1/20 0.31
CYP1B1 Q16678 1/20 0.31
RAB9A P51151 2/20 0.31
KMT2A Q03164 1/20 0.31
ATM Q13315 1/20 0.31
SRPK1 Q96SB4 1/20 0.31
SCN9A Q15858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3070225 0.86 CYP2D6 (0.41) CYP2D6HRH1LTA4HSIGMAR1TLR8
SCHEMBL3076356 0.84 HRH3 (0.42) CYP2D6HRH1LTA4HSIGMAR1RAB9A
SCHEMBL2226301 0.76 CYP2D6 (0.35) CYP2D6HRH1TLR8TLR7TLR9
SCHEMBL30438943 0.76 CXCR4 (0.44) ADORA2AADORA1RAB9AKMT2ANPC1
SCHEMBL18023854 0.75 KMT2A (0.44) CYP2D6HRH1TLR8TLR7TLR9
SCHEMBL6167565 0.75 CXCR4 (0.43) SIGMAR1KMT2A
SCHEMBL17285987 0.75 MC4R (0.42) WNT1GSK3BDYRK1ALRRK2CCR5
SCHEMBL22878259 0.75 LRRK2 (0.35) CYP2D6HRH1TLR8TLR7TLR9
SCHEMBL17284720 0.75 LRRK2 (0.38) CYP2D6HRH1TLR8TLR7TLR9
Hydrochloric Acid SCHEMBL17271881 0.73 CXCR4 (0.42) SIGMAR1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7834015-B2 treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV skin damage, and as chemosensitizers or radiosensitizers for cancer treatment INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2010-11-16 US disclosed
US-20090209523-A1 Pyrrolo[1,2-A] Pyrazin-1(2H)-One and Pyrrolo[1,2-D][1,2,4]Triazin-1(2H)-One Derivatives as Inhibitors of Poly(Adp-Ribose)Polymerase (Parp) ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2009-08-20 US disclosed
EP-2032140-A1 PYRROLO[1,2-A]PYRAZIN-1(2H)-ONE AND PYRROLO[1,2-D][1,2,4]TRIAZIN-1(2H)-ONE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE(PARP) Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) 2009-03-11 EP disclosed
WO-2007138355-A1 PYRROLO[1,2-A]PYRAZIN-1(2H)-ONE AND PYRROLO[1,2-D][1,2,4]TRIAZIN-1(2H)-ONE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE(PARP) ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209523-A1 Pyrrolo[1,2-A] Pyrazin-1(2H)-One and Pyrrolo[1,2-D][1,2,4]Triazin-1(2H)-One Derivatives as Inhibitors of Poly(Adp-Ribose)Polymerase (Parp) PARP1, PARP2, PARP11 CYP2D6 3589/4885HRH1 1962/4885LTA4H 3924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.